Atropine sulfate and Neuroleptic malignant syndrome - a phase IV clinical study of FDA data

Summary:

Neuroleptic malignant syndrome is reported as a side effect among people who take Atropine sulfate (atropine sulfate), especially for people who are male, 40-49 old, have been taking the drug for < 1 month also take Clozapine, and have Dyspnea.

The phase IV clinical study analyzes which people have Neuroleptic malignant syndrome when taking Atropine sulfate. It is created by eHealthMe based on reports of 3,467 people who have side effects when taking Atropine sulfate from the FDA, and is updated regularly.

What is Atropine sulfate?

Atropine sulfate has active ingredients of atropine sulfate. eHealthMe is studying from 3,485 Atropine sulfate users. Check the latest studies of Atropine sulfate.

What is Neuroleptic malignant syndrome?

Neuroleptic malignant syndrome (a life-threatening neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic agents) is found to be associated with 551 drugs and 772 conditions by eHealthMe. Check the latest studies of Neuroleptic malignant syndrome.

On Apr, 25, 2026

3,467 people reported to have side effects when taking Atropine sulfate.
Among them, 14 people (0.4%) have Neuroleptic malignant syndrome.

Could Atropine sulfate cause Neuroleptic malignant syndrome?

Among these 14 people:

How long have people been on Atropine sulfate when they have Neuroleptic malignant syndrome? *

What is the gender of people who have Neuroleptic malignant syndrome when taking Atropine sulfate? *

female: 0.0 %
male: 100 %

What is the age of people who have Neuroleptic malignant syndrome when taking Atropine sulfate? *

What are other drugs people take besides Atropine sulfate? *

What are other side effects people have besides Neuroleptic malignant syndrome? *

Skin Ulcer: 9 people, 64.29%
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 9 people, 64.29%
Metabolic Acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body): 9 people, 64.29%
Iron Deficiency: 9 people, 64.29%
Urine Output Increased: 3 people, 21.43%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 3 people, 21.43%
Blood Creatine Phosphokinase Increased: 3 people, 21.43%
Delusion (a false belief or opinion): 3 people, 21.43%
Depression: 3 people, 21.43%
High Blood Pressure: 3 people, 21.43%

What are the existing conditions these people have? *

Stress And Anxiety: 3 people, 21.43%
High Blood Pressure: 3 people, 21.43%
Dyspnea (difficult or laboured breathing): 3 people, 21.43%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 2 people, 14.29%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 2 people, 14.29%
Pain: 1 person, 7.14%
Infection: 1 person, 7.14%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 7.14%
Gastric Ulcer (stomach ulcer): 1 person, 7.14%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Atropine sulfate and have Neuroleptic malignant syndrome?

- Check whether Neuroleptic malignant syndrome is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Atropine sulfate:

Atropine sulfate (3,485 reports)

Browse all side effects of Atropine sulfate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neuroleptic malignant syndrome:

Neuroleptic malignant syndrome (551 drugs)

Browse all the conditions that are associated with Neuroleptic malignant syndrome:

Neuroleptic malignant syndrome (772 conditions)

Related publications that referenced our studies

Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .
Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on atropine sulfate (the active ingredients of Atropine sulfate) and Atropine sulfate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.